What is new for monoamine neurotransmitter disorders?

Abstract

The monoamine neurotransmitter disorders are increasingly recognized as an expanding group of inherited neurometabolic syndromes caused by disturbances in the synthesis, transport and metabolism of the biogenic amines, including the catecholamines (dopamine, norepinephrine, and epinephrine) and serotonin. Disturbances in monoamine metabolism lead to neurological syndromes that frequently mimic other conditions, such as hypoxic ischemic encephalopathy, cerebral palsy, parkinsonism-dystonia syndromes, primary genetic dystonia and paroxysmal disorders. As a consequence, neurotransmitter disorders are frequently misdiagnosed. Early and accurate diagnosis of these neurotransmitter disorders is important, as many are highly amenable to, and some even cured by, therapeutic intervention. In this review, we highlight recent advances in the field, particularly the recent extensive characterization of known neurotransmitter disorders and identification of novel neurotransmitter disorders. We also provide an overview of current and future research in the field focused on developing novel treatment strategies.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. Allen GF, Land JM, Heales SJ (2009) A new perspective on the treatment of aromatic L-amino acid decarboxylase deficiency. Mol Genet Metab 97(1):6–14

    CAS  PubMed  Article  Google Scholar 

  2. Blackstone C (2009) Infantile parkinsonism-dystonia: a dopamine “transportopathy”. J Clin Invest 119:1455–1458

    CAS  PubMed Central  PubMed  Google Scholar 

  3. Blackstone C (2011) Infantile parkinsonism-dystonia due to dopamine transporter gene mutations: another genetic twist. Lancet Neurol 10(1):24–25

    PubMed  Article  Google Scholar 

  4. Bonafé L, Thőny B, Penzien JM, Czarnecki B, Blau N (2001a) Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet 69:269–277

    PubMed Central  PubMed  Article  Google Scholar 

  5. Bonafé L, Thöny B, Leimbacher W, Kierat L, Blau N (2001b) Diagnosis of dopa-responsive dystonia and other tetrahydrobiopterin disorders by the study of biopterin metabolism in fibroblasts. Clin Chem 47(3):477–485

    PubMed  Google Scholar 

  6. Brasil S, Viecelli HM, Meili D et al (2011) Pseudoexom exclusion by antisense therapy in 6-Pyruvoyl –tetrahydrobiopterin synthase deficiency. Hum Mutat 32:1019–1027

    CAS  PubMed  Article  Google Scholar 

  7. Brun L, Ngu LH, Keng WT (2010) Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology 75(1):64–71

    CAS  PubMed  Article  Google Scholar 

  8. Cawello W, Kim SR, Braun M, Elshoff JP, Ikeda J, Funaki T (2013) Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. Clin Drug Investig. doi:10.1007/s40261-013-0150-5

    PubMed Central  Google Scholar 

  9. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27(3):275–280

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  10. Chang Y, Sharma R, Marsh J et al (2004) Levodopa-responsive aromatic L–amino acid decarboxylase deficiency. Ann Neurol 55(3):435–438

    CAS  PubMed  Article  Google Scholar 

  11. Chi CS, Lee HF, Tsai CR (2012) Tyrosine hydroxylase deficiency in Taiwanese infants. Pediatr Neurol 46(2):77–82

    PubMed  Article  Google Scholar 

  12. De Grandis E, Serrano M, Pérez-Dueñas B et al (2010) Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders. J Inherit Metab Dis 33(6):803–809

    PubMed  Article  Google Scholar 

  13. Eberling JL, Jaqust WJ, Christine CW et al (2008) Results from phase 1 safety trial of hAADC gene therapy for Parkinson disease. Neurology 80:1980–1983

    Article  Google Scholar 

  14. Espay AJ, Chen R (2013) Myoclonus. Continuum (Minneap Minn) 19 (5 Movement Disorders):1264–86

  15. Fernandez-Alvarez E (2009) Movement disorders in children: recent advances in management. Indian J Pediatr 76:531–536

    PubMed  Article  Google Scholar 

  16. Friedman J, Hyland K, Blau N, MacCollin M (2006) Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency. Neurology 67:2032–2035

    PubMed  Article  Google Scholar 

  17. Friedman J, Roze E, Abdenau JE et al (2012) Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 71:520–530

    CAS  PubMed  Article  Google Scholar 

  18. Garcia-Cazorla A, Duarte S, Serrano M et al (2008) Mitochondrial diseases mimicking neurotransmitter defects. Mitochondrion 8(3):273–278

    CAS  PubMed  Article  Google Scholar 

  19. Giovanniello T, Leuzzi V, Carducci C et al (2007) Tyrosine hydroxylase deficiency presenting with a biphasic clinical course. Neuropediatrics 38(4):213–215

    CAS  PubMed  Article  Google Scholar 

  20. Henriksen FH, Yasmeen S, Skjørringe T et al. (2012) Atypical dopamine transporter deficiency syndrome in two adult males with molecular characterisation of new transporter variants. New Orleans, LA: Soc Neurosci Meet Plann 2012, Poster 042

  21. Hwu WL, Muramatsu S, Tseng SH et al (2012) Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med 4(134):134ra61

    PubMed  Google Scholar 

  22. Hyland K, Surtess RAH, Rodeck C, Clayton PT (1992) Aromatic l-amino acid decarboxylase deficiency: clinical features, diagnosis and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 42:1980–1988

    CAS  PubMed  Article  Google Scholar 

  23. Kurian MA (2013) What is the role of dopamine in childhood neurological disorders? Dev Med Child Neurol 55:490–496

    Article  Google Scholar 

  24. Kurian M, Gissen P, Smith M, Heales S, Clayton P (2011a) The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol 10:721–733

    CAS  PubMed  Article  Google Scholar 

  25. Kurian MA, Li Y, Zhen J et al (2011b) Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol 10(1):54–62

    CAS  PubMed  Article  Google Scholar 

  26. Kurian MA, Zhen J, Cheng SY et al (2009) Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. J Clin Invest 119(6):1595–1603

    CAS  PubMed Central  PubMed  Google Scholar 

  27. Lee HF, Tsai CR, Chi CS, Chang TM, Lee HJ (2009) Aromatic L-amino acid decarboxylase deficiency in Taiwan. Eur J Paediatr Neurol 13(2):135–140

    PubMed  Article  Google Scholar 

  28. Leuzzi V, Carducci C, Tolve M, Giannini MT, Angeloni A, Carducci C (2013) Very early pattern of movement disorders in sepiapterin reductase deficiency. Neurology 81(24):2141–2142

    PubMed  Article  Google Scholar 

  29. Lohmann E, Koroglu Ç, Hanagasi H, Dursun B, Tasan E, Tolun A (2012) A homozygous frameshift mutation of sepiapterin reductase gene causing parkinsonism with onset in childhood. Parkinsonism Relat Disord 18(2):191–193

    PubMed  Article  Google Scholar 

  30. Mastrangelo M, Caputi C, Galosi S, Giannini MT, Leuzzi V (2013) Transdermal rotigotine in the treatment of aromatic L-amino acid decarboxylase deficiency. Mov Disord 28(4):556–557

    PubMed  Article  Google Scholar 

  31. Molero-Luis M, Serrano M, Ormazábal A et al (2013) Homovanillic acid in cerebrospinal fluid of 1388 children with neurological disorders. Dev Med Child Neurol 55(6):559–566

    PubMed  Article  Google Scholar 

  32. Moran MM, Allen NM, Treacy EP, King MD (2011) “Stiff neonate” with mitochondrial DNA depletion and secondary neurotransmitter defects. Pediatr Neurol 45(6):403–405

    PubMed  Article  Google Scholar 

  33. Neville BG, Parascandalo R, Farrugia R, Felice A (2005) Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain 128(10):2291–2296

    CAS  PubMed  Article  Google Scholar 

  34. Ng J, Tuschl K, Kinali et al (2013) TH gene-negative infantile onset severe dopamine deficiency syndrome: a novel neurotransmitter disorder? Dev Med Child Neurol 5(S1):15

    Google Scholar 

  35. Ng J, Zhen J, Meyer E et al. (2014) Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain. doi:10.1093/brain/awu022

  36. Pons R, Ford B, Chiriboga CA et al (2004) Aromatic amino acid decarboxylase deficiency: clinical features, treatment, prognosis. Neurology 62:1058–1065

    CAS  PubMed  Article  Google Scholar 

  37. Pons R, Syrengelas D, Youroukos S et al (2013) Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov Disord 28(8):1058–1063

    CAS  PubMed  Article  Google Scholar 

  38. Rilstone J, Alkhater R, Minassian B (2013) Brain dopamine–serotonin vesicular transport disease and its treatment. N Engl J Med 368:543–550

    CAS  PubMed  Article  Google Scholar 

  39. Stamelou M, Mencacci NE, Cordivari C et al (2012) Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology 79(5):435–441

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  40. Swoboda K, Furukawa Y (2008) Tyrosine hydroxylase deficiency. GeneReviewsTM. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK1437/ in December 2013

  41. Tay SK, Poh KS, Hyland K et al (2007) Unusually mild phenotype of AADC deficiency in 2 siblings. Mol Genet Metab 91(4):374–378

    CAS  PubMed  Article  Google Scholar 

  42. Tormenti MJ, Tomycz ND, Coffman KA, Kondziolka D, Crammond DJ, Tyler-Kabara EC (2011) Bilateral subthalamic nucleus deep brain stimulation for dopa-responsive dystonia in a 6-year-old child. J Neurosurg Pediatr 7(6):650–653

    PubMed  Article  Google Scholar 

  43. Verbeek MM, Willemsen MA, Wevers RA et al (2008) Two Greek siblings with sepiapterin reductase deficiency. Mol Genet Metab 94(4):403–409

    CAS  PubMed  Article  Google Scholar 

  44. Willemsen MA, Verbeek MM, Kamsteeg EJ et al (2010) Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 133(6):1810–1822

    PubMed  Article  Google Scholar 

  45. Yeung WL, Wong VC, Chan KY et al (2011) Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency. J Child Neurol 26(2):179–187

    PubMed  Article  Google Scholar 

  46. Zorzi G, Redweik U, Trippe H, Penzien JM, Thöny B, Blau N (2002) Detection of sepiapterin in CSF of patients with sepiapterin reductase deficiency. Mol Genet Metab 75:174–177

    CAS  PubMed  Article  Google Scholar 

Download references

Conflict of interest

None.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Manju A. Kurian.

Additional information

Clara Marecos, Joanne Ng and Manju A Kurian all significantly contributed to the planning, conduct and reporting of the work described in this article.

Communicated by: Nenad Blau

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Marecos, C., Ng, J. & Kurian, M.A. What is new for monoamine neurotransmitter disorders?. J Inherit Metab Dis 37, 619–626 (2014). https://doi.org/10.1007/s10545-014-9697-4

Download citation

Keywords

  • Cerebral Palsy
  • Dystonia
  • Dopamine Agonist
  • Selegiline
  • Pramipexole